BLAINTRAVENOUSVIALPriority Review
Approved
Feb 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
Priority Review
AVASTIN (bevacizumab) by Roche is vascular endothelial growth factor-directed antibody interactions [moa]. Approved for vascular endothelial growth factor inhibitor [epc]. First approved in 2004.
Drug data last refreshed 8h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AVASTIN (bevacizumab) is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF) to block tumor blood vessel formation. It is used across multiple cancer indications and some ophthalmologic conditions, primarily as an adjunct to chemotherapy or other targeted agents. The drug works by starving tumors of their blood supply, slowing disease progression and improving survival in responsive patient populations.
$0.012BPart D
LOE ApproachingDeclining
As AVASTIN approaches loss of exclusivity with strong biosimilar competition, the brand team is likely contracting; focus shifts to defending market share and managing transition strategy rather than growth.
Mechanism of Action
Vascular Endothelial Growth Factor-directed Antibody Interactions
Pharmacologic Class:
Vascular Endothelial Growth Factor Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Safety And Effectiveness Of NaviFUS System With Bevacizumab In Recurrent Glioblastoma
Started Dec 2026
10 enrolled
GBM
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02)
Started Sep 2026
690 enrolled
Ovarian Neoplasms
Efficacy and Safety of Retlirafusp Alfa Plus Bevacizumab and Chemotherapy With or Without Short-Course Radiotherapy in Patients With CRCLM
Started Jul 2026
60 enrolled
CRC (Colorectal Cancer)
IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer
Started Jul 2026
550 enrolled
Colorectal Cancer
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)
Started Jul 2026
646 enrolled
Ovarian CancerPeritoneal CancerFallopian Tube Cancer
Worked on AVASTIN at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.